 85 subjects were randomized into one of 3 treatment arms with equal probability. In treatment arm 1, subjects will receive BMS-201038 AEGR-733 5 mg plus ezetimibe placebo. In treatment arm 2, subjects will receive BMS-201038 AEGR-733 placebo plus 10 mg of ezetimibe. In treatment arm 3, subjects will receive BMS-201038 AEGR-733 5 mg plus ezetimibe 10 mg. After 4 weeks of treatment, subjects in arms 1 and 3 will be force-titrated to BMS-201038 AEGR-733 7.5 mg. After another 4 weeks of treatment, subjects in arms 1 and 3 will then be force-titrated to BMS-201038 AEGR-733 10 mg for 4 more additional weeks of treatment. Subjects in arm 2 will continue to receive BMS-201038 AEGR-733 matching placebo for the entire 12 weeks of treatment. Subjects randomized to ezetimibe 10 mg in arms 2 and 3 and ezetimibe placebo in arm 1 will remain on these doses for the entire 12-week treatment period. 